The report covers emerging Alopecia Areata drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Alopecia Areata treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Alopecia Areata: An Overview
Alopecia Areata (AA) is a common autoimmune skin disease, which causes hair loss on the scalp, face, and at times other areas of the body. The affected hair follicles are attacked by a person’s immune system (white blood cells), which results in the seizing of the hair growth stage. Hair follicles remain alive, and hair can regrow anytime in Alopecia Areata.
Alopecia Areata usually begins with one or more patches which may be small, round, or smooth on the scalp that can progress to total scalp hair loss or complete body hair loss. Genetic predisposition and environmental factors increase the chances of developing alopecia areata. Alopecia Areata develops in people of different age groups and affects all ethnic groups. It often first appears during childhood and can be different for people who develop it. This autoimmune disorder is quite a common yet challenging and capricious disease. Alopecia (hair loss) can be of different types: Alopecia areata (hair loss in patches), Alopecia totalis (loss of all hair on the scalp), Alopecia universalis (loss of all hair on the body).
Alopecia Areata Market is expected to grow immensely in the coming years owing to the rise in the number of cases of Alopecia Areata and the extensive R&D activities by academics and companies such as Pfizer, Eli Lilly, and others in the therapeutics market to develop novel therapies.
Alopecia Areata Market Key Facts
-
According to Miteva et al. (2015), the lifetime incidence of AA is approximately 2% worldwide. AA has no sex predominance, it affects both the male and female populations equally. The first onset of AA is most common in the third and fourth decades of life but may occur at any age.
-
According to NICE, alopecia areata is estimated to affect 15 in 10,000 people in the UK. It can present at any age, and males and females are affected equally.
-
A study by Macey J. et al. stated that a slightly higher prevalence of 2.5% has been reported in Japan for Alopecia areata.
-
Currently, some of the key players involved in the development of novel drugs include Pfizer (PF-06651600), Legacy Healthcare SA (LH-8), Concert Pharmaceuticals (CTP-543), Pfizer (Ritlecitinib), and Suzhou Zelgen Biopharmaceuticals (Jaktinib hydrochloride tablets) among others.
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Alopecia Areata pipeline therapies. It also thoroughly assesses the Alopecia Areata market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete detail of the market trend for each marketed Alopecia Areata drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.
Alopecia Areata Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted Alopecia Areata epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted Alopecia Areata epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders.
The Report Covers the Alopecia Areata Epidemiology, Segmented as –
-
Prevalent Cases of Alopecia Areata in the 7MM [2019–2032]
-
Subtype-specific Cases of Alopecia Areata in the 7MM [2019–2032]
-
Diagnosed Cases of Alopecia Areata in the 7MM [2019–2032]
-
Age-specific Cases of Alopecia Areata in the 7MM [2019–2032]
Alopecia Areata Drugs Uptake and Pipeline Development Activities
The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Alopecia Areata market or expected to be launched during the study period. The analysis covers the Alopecia Areata market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares the Alopecia Areata drugs based on their sale and market share.
The report also covers the Alopecia Areata pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key Alopecia Areata companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How the Alopecia Areata Market Will Evolve and Grow by 2032 @
https://www.delveinsight.com/sample-request/alopecia-areata-market
Latest Clinical, Commercial, and Regulatory Developments in the Alopecia Areata Therapeutics Market
“On June 19, 2023, Legacy Healthcare announced that its Marketing Authorisation Application (MAA) to the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) for Coacillium for the treatment of moderate and severe alopecia areata in children and adolescents has been validated and is now under CHMP review.”
“On May 18, 2023, ASLAN Pharmaceuticals (NASDAQ: ASLN) announced that it has dosed the first patient in a Phase 2a proof-of-concept study of farudodstat, an oral dihydroorotate dehydrogenase (DHODH) inhibitor, in adult patients with severe alopecia areata (AA), an autoimmune condition causing hair loss. The study, called “FAST-AA” (FArudodstat STudy in Alopecia Areata), will investigate farudodstat’s efficacy and safety in patients with at least 50% scalp hair loss.”
“On February 15, 2023, Concert Pharmaceuticals, Inc. announced that, after a recent review of deuruxolitinib clinical data by the U.S. Food and Drug Administration (FDA), the FDA determined that deuruxolitinib will maintain its Breakthrough Therapy designation. Deuruxolitinib, an oral Janus kinase (JAK) inhibitor, is being developed for the treatment of adult patients with moderate to severe alopecia areata.”
Alopecia Areata Therapeutics Analysis
Several major pharma and biotech giants are developing therapies for Alopecia Areata. Currently, Pfizer is leading the therapeutics market with its Alopecia Areata drug candidates in the most advanced stage of clinical development.
Alopecia Areata Companies Actively Working in the Therapeutics Market Include
-
Aclaris Therapeutics
-
Arcutis Biotherapeutics
-
Arena Pharmaceuticals
-
Bioniz
-
Concert Pharmaceutical
-
Eli Lilly and Company
-
HCW Biologics
-
Incyte Corp.
-
Legacy Healthcare
-
LEO Pharma
-
Novartis
-
Pfizer
-
Reistone Biopharma Company
-
Rigel Pharmaceuticals
And many others
Emerging and Marketed Alopecia Areata Therapies Covered in the Report Include:
-
ARQ 255: Arcutis Biotherapeutics
-
Deuruxolitinib: Concert Pharmaceuticals
-
HCW 9302:HCW Biologics
-
LH-8: Legacy Healthcare
-
Ritlecitinib: Pfizer
-
SHR0302: Reistone Biopharma Company
And many more
The Report Covers the In-depth Assessment of the Emerging Drugs & Key Companies. Download the Sample Report to Learn More @
https://www.delveinsight.com/sample-request/alopecia-areata-market
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Alopecia Areata Competitive Intelligence Analysis
4. Alopecia Areata Market Overview at a Glance
5. Alopecia Areata Disease Background and Overview
6. Alopecia Areata Patient Journey
7. Alopecia Areata Patient Population and Epidemiology Trends (In the US, EU5, and Japan)
8. Alopecia Areata Treatment Algorithm, Current Treatment, and Medical Practices
9. Alopecia Areata Unmet Needs
10. Key Endpoints of Alopecia Areata Treatment
11. Alopecia Areata Marketed Therapies
12. Alopecia Areata Emerging Drugs and Latest Therapeutic Advances
13. Alopecia Areata Seven Major Market Analysis
14. Attribute Analysis
15. Alopecia Areata Market Outlook (In US, EU5, and Japan)
16. Alopecia Areata Companies Active in the Market
17. Alopecia Areata Access and Reimbursement Overview
18. KOL Views on the Alopecia Areata Market
19. Alopecia Areata Market Drivers
20. Alopecia Areata Market Barriers
21. Appendix
22. DelveInsight Capabilities
23. Disclaimer
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download the Sample PDF to Learn More About the Key Offerings of the Report @
https://www.delveinsight.com/sample-request/alopecia-areata-market
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Other Trending Healthcare Reports by DelveInsight
“Substance Use Disorder Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Substance Use Disorder market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Substance Use Disorder market.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/